The Role of Nanotechnology in Targeted Drug Delivery Systems for Cancer Treatment

Nanotechnology has emerged as a transformative approach in cancer treatment through the development of targeted drug delivery systems. These systems utilize nanoparticles to deliver therapeutic agents precisely to cancer cells, thereby minimizing damage to healthy tissues and enhancing treatment efficacy. This review explores various nanocarriers, including liposomes, dendrimers, solid lipid nanoparticles, gold nanoparticles, and polymeric nanoparticles, highlighting their mechanisms and clinical applications. Passive targeting, driven by the Enhanced Permeability and Retention (EPR) effect, and active targeting, facilitated by ligand-receptor interactions, represent key strategies in these delivery systems. Additionally, stimuli-responsive nanoparticles that release drugs in response to environmental triggers, such as pH or temperature changes, offer promising advancements for controlled drug delivery. The advantages of nanotechnology-based drug delivery include improved drug bioavailability, reduced systemic toxicity, and enhanced patient compliance through lower dosing requirements. Despite significant advancements, challenges such as nanoparticle toxicity, regulatory hurdles, and scalability issues persist, hindering the widespread clinical adoption of these systems. Future research should focus on optimizing nanoparticle design, ensuring long-term safety, and developing standardized regulatory protocols. The integration of nanotechnology with personalized medicine holds immense potential for more effective, patient-specific cancer therapies, marking a significant step forward in oncology care.